| 发明名称 |
Treatment of transcription factor E3 (TFE3) and insulin receptor substrate 2(IRS2) related diseases by inhibition of natural antisense transcript to TFE3 |
| 摘要 |
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotides, in particular, by targeting natural antisense polynucleotides of Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of TFE3 and/or IRS2. |
| 申请公布号 |
US8895527(B2) |
申请公布日期 |
2014.11.25 |
| 申请号 |
US201013321863 |
申请日期 |
2010.05.21 |
| 申请人 |
|
发明人 |
Collard Joseph;Khorkova Sherman Olga |
| 分类号 |
C12N15/11;A61K31/713;C12N15/113 |
主分类号 |
C12N15/11 |
| 代理机构 |
CuRNA, Inc. |
代理人 |
CuRNA, Inc. ;Browder Monte R. |
| 主权项 |
1. A method of upregulating a function of and/or the expression of an Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotide in cells or tissues in vivo or in vitro comprising:
contacting, said cells or tissues with at least one antisense oligonucleotide of 15-30 nucleotides in length that specifically targets a region of a natural antisense polynucleotide of the Transcription factor E3 (TFE3) polynucleotide comprising SEQ ID NO: 3; thereby upregulating a function of and/or the expression of the Transcription factor E3 (TFE3) and/or Insulin Receptor Substrate 2 (IRS2) polynucleotide in cells or tissues in vivo or in vitro. |
| 地址 |
|
